AVROBIO logo
AVROBIO AVRO
report update icon

Quarterly report 2026-Q2
added 08-06-2026

AVROBIO Income Statement 2025-2011 | AVRO

Annual Income Statement AVROBIO

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - 1.61 M 54.7 M 62.1 K 522 M 566 M 174 M - - - - - - -

Shares

18.3 M 8.49 M 1.27 M 43.7 M 42.9 K 36.4 M 27.4 M 13.4 M - - - - - - -

Historical Prices

- - 1.27 1.25 1.45 11 19.3 16.7 - - - - - - -

Net Income

-74.2 B -58 B -42.8 B -106 M -119 M -120 M -73 M -46.4 M -18.6 M -4.66 M - - - - -

Operating Income

-84 M -58 M -44.6 M -105 M -119 M -120 M -75.8 M -46.2 M -18.4 M - - - - - -

Interest Expense

-119 K -511 K 396 K - - - - - - - - - - - -

EBITDA

-82.7 M -56.4 M -43.2 M -104 M -117 M -119 M -75 M -45.9 M -18 M -4.59 M - - - - -

Operating Expenses

84 M 58 M 44.6 M 105 M 119 M 120 M 75.8 M 46.2 M - - - - - - -

General and Administrative Expenses

20.5 M 16.7 M 7.68 M 33.2 M 35.7 M 33 M 20.8 M 11.1 M 3.2 M 1.96 M - - - - -

All numbers in USD currency

Quarterly Income Statement AVROBIO

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

19 M 18.8 M 18.7 M 18.7 M 17.2 M 14.9 M 14.7 M 2.92 M 1.39 M 2.63 M 1.32 M 1.23 M 44 M 43.9 M 43.8 M 43.7 M 43.7 K 43.7 M 43.6 K 42.5 K 41.6 M 43.7 M 36.4 M 36.1 M 33.7 M 31.6 M 30.3 M 24 M 23.9 M 23.8 M 23.7 M 3.53 M 2.32 M 2.31 M 2.26 M 2.2 M - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-22.3 M -25.2 M -19 M -20 M -15.9 M - -17.7 M -12.7 M -15.2 M - -10.1 M -10.5 M -25 M - -23 M -28.1 M -29.8 M - -32.6 M -31.4 M -26.9 M - -36.8 M -28.8 M -26 M - -17.1 M -16.1 M -17.1 M - -11.6 M -10.5 M -8.24 M - -6.44 M -2.53 M - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-24.2 M -27.3 M -21.9 M -22.3 M -18.3 M - -19.6 M -11.4 M -13 M - -10.1 M -10.6 M -25.2 M - -23 M -27.8 M -29.4 M - -32.6 M -31.4 M -26.9 M - -36.7 M -28.9 M -26.6 M - -18.1 M -16.6 M -17.7 M - -12.2 M -9.55 M -7.79 M - -6.37 M -2.54 M - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

-5 K -113 K -31 K -48 K -32 K - -7 K -5 K -403 K - -1 K -8 K 15 K - -95 K 5 K -45 K - 5 K -21 K - - -74 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-23.6 M -27 M - - -17.9 M - -19.4 M -11.2 M -12.6 M - -9.86 M -10.4 M -24.9 M - -22.6 M -27.4 M -29 M - -32.2 M -31.1 M -26.6 M - -36.4 M -28.6 M -26.3 M - -17.8 M -16.2 M -17.5 M - -12 M -9.48 M -7.77 M - -6.34 M -2.53 M - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

24.2 M 27.3 M 21.9 M 22.3 M 18.3 M - 19.6 M 11.4 M 13 M - 10.1 M 10.6 M 25.2 M - 23 M 27.8 M 29.4 M - 32.6 M 31.4 M 26.9 M - 36.7 M 28.9 M 26.6 M - 18.1 M 16.6 M 17.7 M - 12.2 M 9.55 M 7.79 M - 6.37 M 2.54 M - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

6.17 M 6.43 M 4.96 M 5.15 M 5.26 M - 5.32 M 4.35 M 2.15 M - 1.98 M 1.86 M 7.89 M - 7.07 M 8.9 M 10.2 M - 9.58 M 8.83 M 8.36 M - 8.21 M 7.99 M 8.32 M - 5.02 M 4.34 M 5.25 M - 3 M 2.14 M 2.14 M - 959 K 661 K - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company AVROBIO (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bio-Path Holdings Bio-Path Holdings
BPTH
- - $ 100 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
- -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Diffusion Pharmaceuticals Diffusion Pharmaceuticals
DFFN
- 11.68 % $ 8.97 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
- -5.68 % $ 8.28 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
- - $ 661 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
- 7.55 % $ 38.1 M usaUSA
Eyenovia Eyenovia
EYEN
- 49.81 % $ 13.2 M usaUSA
FibroGen FibroGen
FGEN
- - $ 889 M usaUSA
Homology Medicines Homology Medicines
FIXX
- 0.77 % $ 53.4 M usaUSA
Amicus Therapeutics Amicus Therapeutics
FOLD
- - $ 4.47 B usaUSA
Frequency Therapeutics Frequency Therapeutics
FREQ
- - $ 528 M usaUSA
Galecto Galecto
GLTO
- - $ 762 M danmarkDanmark
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Graybug Vision Graybug Vision
GRAY
- -11.23 % $ 9.65 M usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
Hoth Therapeutics Hoth Therapeutics
HOTH
- - $ 18.8 M usaUSA
IMARA IMARA
IMRA
- 15.96 % $ 663 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
- - $ 1.45 B britainBritain
KemPharm KemPharm
KMPH
- -0.34 % $ 200 M usaUSA
Kezar Life Sciences Kezar Life Sciences
KZR
- - $ 53.3 M usaUSA
Lixte Biotechnology Holdings Lixte Biotechnology Holdings
LIXT
- - $ 63.4 M usaUSA
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
Magenta Therapeutics Magenta Therapeutics
MGTA
- -7.74 % $ 41.6 M usaUSA
NovaBay Pharmaceuticals NovaBay Pharmaceuticals
NBY
- - $ 11.3 M usaUSA
NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals
NRBO
- 0.43 % $ 12 M usaUSA
OncoCyte Corporation OncoCyte Corporation
OCX
- 17.22 % $ 355 K usaUSA
Onconova Therapeutics Onconova Therapeutics
ONTX
- -0.47 % $ 21 M usaUSA
Opthea Limited Opthea Limited
OPT
- - $ 1.2 B australiaAustralia
BiomX BiomX
PHGE
$ 1.85 14.2 % $ 3.02 M israelIsrael
Pieris Pharmaceuticals Pieris Pharmaceuticals
PIRS
- -15.58 % $ 1.22 B germanyGermany
Plus Therapeutics Plus Therapeutics
PSTV
- - $ 301 M usaUSA
Pluristem Therapeutics Pluristem Therapeutics
PSTI
- -1.9 % $ 33.3 M israelIsrael
Qualigen Therapeutics Qualigen Therapeutics
QLGN
- 5.59 % $ 1.16 M usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Cassava Sciences Cassava Sciences
SAVA
- - $ 110 M usaUSA
Selecta Biosciences Selecta Biosciences
SELB
- -8.69 % $ 126 M usaUSA
Sangamo Therapeutics Sangamo Therapeutics
SGMO
- - $ 50.4 M usaUSA
Salarius Pharmaceuticals Salarius Pharmaceuticals
SLRX
- - $ 2.64 M usaUSA
Sensei Biotherapeutics Sensei Biotherapeutics
SNSE
- - $ 17.5 M usaUSA